FluoroPharma Medical Announces Phase II Study for BFPET(TM) (18)F-TPP
Massachusetts General Hospital Selected as Trial Site for Next Generation Diagnostic Agent for Use in Patients with Coronary Artery Disease MONTCLAIR, NJ– 01/03/13 — FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development […]